Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission
详细信息 查看全文
- 作者：Andrew J. Cowan1 ; Philip A. Stevenson1 ; Ryan D. Cassaday1 ; Solomon A. Graf1 ; Jonathan R. Fromm2 ; David Wu2 ; Leona A. Holmberg1 ; Brian G. Till1 ; Thomas R. Chauncey1 ; 3 ; Stephen D. Smith1 ; Mary Philip1 ; Johnnie J. Orozco1 ; Andrei R. Shustov1 ; Damian J. Green1 ; Edward N. Libby III4 ; William I. Bensinger1 ; Mazyar Shadman1 ; David G. Maloney5 ; Oliver W. Press1 ; Ajay K. Gopal1 ; agopal@u.washington.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Mantle cell lymphoma ; Transplantation ; Minimal residual disease ; Predictors ; Survival
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：22
- 期：2
- 页码：380-385
- 全文大小：189 K
文摘
- •
Autologous stem cell transplantation is standard therapy for mantle cell lymphoma.
- •
We hypothesize that minimal residual disease could stratify outcomes for transplantation.
- •
Minimal residual disease positivity was associated with shorter overall survival and progression-free survival.
- •
Minimal residual disease positivity is independently associated with poor outcome after transplantation.